LeMaitre Vascular will announce Q4 2024 results on February 27, 2025, with a conference call at 5 PM EST.
Quiver AI Summary
LeMaitre Vascular, Inc. announced that it will release its fourth quarter 2024 financial results on February 27, 2025, after market close. A conference call is scheduled for 5:00 PM EST that same day to discuss the results and company outlook, with access available through online registration. The audio webcast can be accessed live or via replay on LeMaitre's website. The company specializes in devices and services for treating peripheral vascular disease, serving vascular surgeons worldwide. More information can be found on their website.
Potential Positives
- LeMaitre Vascular will be providing insights into its fourth quarter 2024 financial results, which can signal transparency and engagement with stakeholders.
- The scheduled conference call presents an opportunity for the company to highlight business achievements and future outlook, potentially fostering investor confidence.
- The mention of the company's focus on peripheral vascular disease, affecting over 200 million people globally, underscores the significance of its product offerings and market potential.
Potential Negatives
- e
FAQ
What date will LeMaitre Vascular release its Q4 2024 financial results?
LeMaitre Vascular will release its Q4 2024 financial results on February 27, 2025, after market close.
How can I access the conference call for LeMaitre's financial results?
You can access the conference call by registering online. Registrants will receive dial-in information and a PIN.
What time is the LeMaitre Vascular conference call scheduled?
The conference call to discuss the financial results is scheduled for 5:00 PM EST on February 27, 2025.
Where can I find the audio webcast for the LeMaitre call?
The audio webcast can be accessed live or via replay at www.lemaitre.com/investor.
What products does LeMaitre Vascular provide?
LeMaitre Vascular provides devices, implants, and services for the treatment of peripheral vascular disease affecting millions globally.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$LMAT Insider Trading Activity
$LMAT insiders have traded $LMAT stock on the open market 6 times in the past 6 months. Of those trades, 0 have been purchases and 6 have been sales.
Here’s a breakdown of recent trading of $LMAT stock by insiders over the last 6 months:
- BRIDGET A ROSS sold 3,750 shares for an estimated $380,512
- DAVID B ROBERTS (President and Director) sold 3,063 shares for an estimated $251,380
- MARTHA SHADAN has made 0 purchases and 2 sales selling 1,466 shares for an estimated $151,547.
- LAWRENCE J JASINSKI sold 198 shares for an estimated $20,493
- TRENT G KAMKE (Senior V. P., Operations) sold 182 shares for an estimated $14,891
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$LMAT Hedge Fund Activity
We have seen 134 institutional investors add shares of $LMAT stock to their portfolio, and 121 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- CONESTOGA CAPITAL ADVISORS, LLC removed 285,517 shares (-14.4%) from their portfolio in Q4 2024, for an estimated $26,307,536
- CRAMER ROSENTHAL MCGLYNN LLC removed 249,029 shares (-100.0%) from their portfolio in Q3 2024, for an estimated $23,132,303
- BLACKROCK, INC. added 200,027 shares (+5.8%) to their portfolio in Q3 2024, for an estimated $18,580,508
- KAYNE ANDERSON RUDNICK INVESTMENT MANAGEMENT LLC added 194,540 shares (+inf%) to their portfolio in Q3 2024, for an estimated $18,070,820
- RANGER INVESTMENT MANAGEMENT, L.P. removed 128,458 shares (-15.8%) from their portfolio in Q3 2024, for an estimated $11,932,463
- KENNEDY CAPITAL MANAGEMENT LLC removed 73,289 shares (-37.4%) from their portfolio in Q3 2024, for an estimated $6,807,815
- DIMENSIONAL FUND ADVISORS LP removed 65,548 shares (-10.2%) from their portfolio in Q3 2024, for an estimated $6,088,753
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
BURLINGTON, Mass., Jan. 27, 2025 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that it will release its fourth quarter 2024 financial results on Thursday, February 27, 2025, after the market close. The company has scheduled a conference call for 5:00 PM EST the same day to discuss the results, business highlights, and company outlook.
Access to the live call is available by registering online here . All registrants will receive dial-in information and a PIN allowing them to access the live call. The audio webcast can also be accessed live or via replay through a webcast at www.lemaitre.com/investor .
About LeMaitre
LeMaitre is a provider of devices, implants, and services for the treatment of peripheral vascular disease, a condition that affects more than 200 million people worldwide. The Company develops, manufactures, and markets disposable and implantable vascular devices to address the needs of its core customer, the vascular surgeon. Additional information can be found at www.lemaitre.com .
LeMaitre and the LeMaitre logo are registered trademarks of LeMaitre Vascular, Inc.